Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2088MR)

This product GTTS-WQ2088MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2088MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3506MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ8948MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14390MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ13708MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ1849MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ12581MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ8804MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ6774MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS-1062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW